— Know what they know.
Not Investment Advice

CTLT NYSE

Catalent, Inc.
1W: +2.0% 1M: +7.4% 3M: +5.2% 1Y: +53.0% 3Y: -48.1% 5Y: +21.6%
$63.48
Last traded 2024-12-17 — delisted
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · $11.5B mcap · 180M float · 1.24% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$11.5B
52W Range42.11-63.5
Volume13,674,041
Avg Volume2,229,391
Beta1.16
Dividend—
Analyst Ratings
8 Buy 12 Hold 1 Sell
Consensus Hold
Company Info
CEOAlessandro Maselli
Employees17,000
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2014-07-31
14 Schoolhouse Road
Somerset, NJ 08873
US
732 537 6200
About Catalent, Inc.

Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Gennadios Aristippos A-Award 21,562 — 2024-12-18
Gennadios Aristippos D-Return 21,562 — 2024-12-18
McErlane David A-Award 11,426 — 2024-12-18
McErlane David D-Return 14,740 $45.79 2024-12-18
McErlane David D-Return 11,426 — 2024-12-18

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms